M. Robyn Andersen
M.P.H., University of Washington, Public Health, 1996.
Ph.D., State University of New York at Stony Brook, Social Psychology, 1994.
M.A., State University of New York at Stony Brook, Psychology, 1992.
As advances in medical care only improve public health when they are adopted and used by patients and physicians, my research examines issues related to the adoption of medical technologies for the prevention and treatment of cancer. In my work I try to bridge the disciplines of Health Psychology and Epidemiology using behavioral theory to understand the effect of medical interventions on people's understanding of their health and to develop interventions to improve public health.
This work has included; examinations of the effects of cancer screening on at risk women's sense of well being, and the effects of involvement in decision-making about testing for recurrant disease after cancer on breast cancer survivors' quality of life, effects of decision making about cancer treatment on cancer survivor's quality of life, and most recently on the effects of CAM use on cancer screening and diagnosis.
I am currently involved in projects examining psychosocial predictors of quality of life for breast and ovarian cancer survivors, the influence of CAM on cancer diagnosis and treatment and the potential of a symptoms index to improve early diagnosis of ovarian cancer.
American Psychological Association
American Society of Preventive Oncology
Society of Behavioral Medicine
Honors and Awards
2002, Best Paper Award, Health Education and Behavior
2000-2002, Career Development Award, Pacific Ovarian Cancer Research Consortium Specialized program of research excellence (SPORE)
1996, New Young Investigator, American Society of Preventive Oncology
1994-1996, Post-doctoral Trainee, National Institutes of Health Training Grant, Cancer Prevention
1993, Contribution to Undergraduate Teaching Award, State University of New York @ Stony Brook
2003-1012, Associate Member, Fred Hutchinson Cancer Research Center, Cancer Prevention, Public Health Sciences Division
1997-2003, Assistant Member, Fred Hutchinson Cancer Research Center, Cancer Prevention, Public Health Sciences Division
1996-1997, Staff Scientist, Fred Hutchinson Cancer Research Center, Public Health Sciences Division
1994-1996, Postdoctoral Fellow, Fred Hutchinson Cancer Research Center, Public Health Sciences Division
Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.. 2014.
Value of symptom-triggered diagnostic evaluation for ovarian cancer.. Obstetrics and gynecology. 123(1):73-9.. 2014.
Dangerous Combinations: Ingestible CAM Supplement Use During Chemotherapy in Patients with Ovarian Cancer.. Journal of alternative and complementary medicine (New York, N.Y.).. 2013.
Adverse Events Associated With Complementary and Alternative Medicine Use in Ovarian Cancer Patients.. Integrative cancer therapies.. 2013.
Adverse Events Associated With Complementary and Alternative Use in Ovarian Cancer Patients - editorial comment. Obstetrical & Gynecological Survey. 68:741-742.. 2013.
Involvement in decision-making about treatment and ovarian cancer survivor quality of life.. Gynecologic oncology. 124(3):465-470.. 2012.
Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability.. Gynecologic oncology. 124(2):230-5.. 2012.
Symptoms of breast cancer in an age of technologic screening.. Journal of women's health (2002). 20(8):1129-31.. 2011.
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.. Gynecologic oncology. 116(3):378-83.. 2010.
Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 18(5):1365-72.. 2009.
Psychological and social risk factors in adolescent smoking transitions: a population-based longitudinal study.. Health psychology : official journal of the Division of Health Psychology, American Psychological Association. 28(4):439-47.. 2009.
Involvement in decision-making and breast cancer survivor quality of life.. Health psychology : official journal of the Division of Health Psychology, American Psychological Association. 28(1):29-37.. 2009.
The temporal stability of the Symptom Index among women at high-risk for ovarian cancer.. Gynecologic oncology. 114(2):225-30.. 2009.
Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 17(9):2480-7.. 2008.
Complementary and alternative medicine provider use and expenditures by cancer treatment phase.. The American journal of managed care. 14(5):326-34.. 2008.
Combining a symptoms index with CA 125 to improve detection of ovarian cancer.. Cancer. 113(3):484-9.. 2008.
Frequent search for sense by long-term breast cancer survivors associated with reduced HRQOL.. Women & health. 47(4):19-37.. 2008.
Parents' and older siblings' smoking during childhood: changing influences on smoking acquisition and escalation over the course of adolescence.. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. 9(9):915-26.. 2007.
The role of schoolmates' smoking and non-smoking in adolescents' smoking transitions: a longitudinal study.. Addiction (Abingdon, England). 102(10):1665-75.. 2007.
Changes in the influence of parents' and close friends' smoking on adolescent smoking transitions.. Addictive behaviors. 32(4):740-57.. 2007.